Sirona Biochem Corp. (V:SBM*CA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: Sirona Biochem Corp. (c/o WeWork)
Tel: N/A
IR: See website
Key People
Howard Verrico
Chairman of the Board, Interim Chief Executive Officer, Founder, Secretary
Christopher D. Hopton
Chief Financial Officer, Director
Geraldine Deliencourt-Godefroy
Chief Scientific Officer, Director
Attila Hajdu
Chief Business Development Officer
Business Overview
Sirona Biochem Corp. is a Canada-based development-stage cosmetic ingredient and drug discovery company with a technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. It is engaged in the development of cosmetic and pharmaceutical active ingredients, which are licensed to its partners. The Company has six product lines: SGLT2 Inhibitor, Skin Lightener I, GlycoProteMin-Anti aging, Anti-inflammatory, Anti-infective and Skin Lightener II. Its development is focused on three programs: therapeutics, which includes diabetes, anti-inflammatories and anti-infectives; cosmeceuticals, which includes anti-aging and depigmenting agents (skin lighteners), and biological ingredients, which includes inducers and adjuvants for biological development and preservation. The Company, through TFChem S.A.R.L. (TFC), is engaged in using fluorine atom properties to develop glycomimetic compounds.
Financial Overview
For the three months ended 31 January 2019, Sirona Biochem Corp revenues decreased 89% to C$65K. Net loss increased from C$118K to C$582K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Consulting fees increase from C$45K to C$144K (expense), Investor relations increase from C$16K to C$56K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $103.07M as of Jan 31, 2019
Annual revenue (TTM): $0.78M as of Jan 31, 2019
EBITDA (TTM): -$1.41M as of Jan 31, 2019
Net annual income (TTM): -$1.74M as of Jan 31, 2019
Free cash flow (TTM): -$1.08M as of Jan 31, 2019
Net Debt Last Fiscal Year: $2.45M as of Jan 31, 2019
Shares outstanding: 210,200,451 as of Jun 12, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization